Capricor Therapeutics Q3 EPS $(0.25) Vs $(0.26) Last Year, Sales $6.18M Beat $2.11M Estimate
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) reported a narrower Q3 loss of $(0.25) per share compared to $(0.26) last year, with sales of $6.18M significantly exceeding the $2.11M estimate, marking a 288.51% increase from the previous year.
November 14, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics reported a smaller loss per share and a substantial increase in sales, surpassing analyst estimates for Q3.
The positive earnings report, with a reduced loss per share and sales that greatly exceeded expectations, is likely to instill investor confidence and could lead to a short-term increase in the stock price of Capricor Therapeutics.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100